A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Actuate Therapeutics Inc.
University of Southern California
Incyte Corporation
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Hummingbird Bioscience
Cyteir Therapeutics, Inc.
Eli Lilly and Company
Coherus Oncology, Inc.
Syros Pharmaceuticals
Northwestern University
Bayer
Gilead Sciences
Celgene
Western Regional Medical Center
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Northwestern University
Altor BioScience
Amgen
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)